1
|
Kicova M, Michalova Z, Coma M, Gabzdilova J, Dedinska K, Guman T, Bernatova S, Hajikova M, Giertlova M, Veselinyova D, Sarissky M. The expression of CD73 on pathological B-cells is associated with shorter overall survival of patients with CLL. Neoplasma 2020; 67:933-938. [PMID: 32266820 DOI: 10.4149/neo_2020_190826n822] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/26/2019] [Accepted: 12/08/2019] [Indexed: 11/08/2022]
Abstract
CD73 is a membrane-bound enzyme that catalyzes the extracellular conversion of adenosine monophosphate to adenosine. Adenosine is thought to play a role in promoting tumor growth and survival together with suppressing the host immune responses, which contribute to the multistep process of tumorigenesis. Here, we studied the expression of this antigen in chronic lymphocytic leukemia (CLL). The expression of CD73 was analyzed by multiparametric flow cytometry on normal and pathological B-cells from peripheral blood and bone marrow samples from 71 patients with CLL. Pathological B-cells expressed significantly lower levels of CD73 than normal B-cells (p<0.01). Patients with splenomegaly showed a higher expression of CD73 on pathological B-cells than patients without splenomegaly (p<0.05). The expression of CD73 also correlated with beta-2-microglobulin levels (p<0.05). Clinically, patients with higher levels of CD73 versus those with lower expression presented with shorter overall survival (median OS of 65 vs. 113 months, p<0.05). Our data indicate that CD73 may play a role in CLL pathophysiology, is correlated with poor clinical and biological prognostic factors and may be of potential value as a prognostic marker and therapeutic target.
Collapse
Affiliation(s)
- M Kicova
- Central Laboratory of Clinical Cytometry, Department of Pharmacology, Faculty of Medicine, P.J. Safarik University and Medirex, a.s., Kosice, Slovakia.,Department of Pharmacology, Faculty of Medicine, P.J. Safarik University, Kosice, Slovakia
| | - Z Michalova
- Central Laboratory of Clinical Cytometry, Department of Pharmacology, Faculty of Medicine, P.J. Safarik University and Medirex, a.s., Kosice, Slovakia.,Department of Pharmacology, Faculty of Medicine, P.J. Safarik University, Kosice, Slovakia
| | - M Coma
- Department of Pharmacology, Faculty of Medicine, P.J. Safarik University, Kosice, Slovakia
| | - J Gabzdilova
- Department of Hematology and Oncohematology, Louis Pasteur University Hospital and Faculty of Medicine, P.J. Safarik University, Kosice, Slovakia
| | - K Dedinska
- Department of Hematology and Oncohematology, Louis Pasteur University Hospital and Faculty of Medicine, P.J. Safarik University, Kosice, Slovakia
| | - T Guman
- Department of Hematology and Oncohematology, Louis Pasteur University Hospital and Faculty of Medicine, P.J. Safarik University, Kosice, Slovakia
| | - S Bernatova
- Central Laboratory of Clinical Cytometry, Department of Pharmacology, Faculty of Medicine, P.J. Safarik University and Medirex, a.s., Kosice, Slovakia.,Department of Pharmacology, Faculty of Medicine, P.J. Safarik University, Kosice, Slovakia
| | - M Hajikova
- Central Laboratory of Clinical Cytometry, Department of Pharmacology, Faculty of Medicine, P.J. Safarik University and Medirex, a.s., Kosice, Slovakia.,Department of Pharmacology, Faculty of Medicine, P.J. Safarik University, Kosice, Slovakia
| | - M Giertlova
- Department of Clinical Genetics, Medirex, a.s., Kosice, Slovakia
| | - D Veselinyova
- Department of Clinical Genetics, Medirex, a.s., Kosice, Slovakia
| | - M Sarissky
- Central Laboratory of Clinical Cytometry, Department of Pharmacology, Faculty of Medicine, P.J. Safarik University and Medirex, a.s., Kosice, Slovakia.,Department of Pharmacology, Faculty of Medicine, P.J. Safarik University, Kosice, Slovakia
| |
Collapse
|